| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.17 | 0.003 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | 0.49 | 0.005 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.005 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.098 | 0.005 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.095 | 0.005 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.005 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.085 | 0.005 |